Accelerated Pharma (PRIVATE.ACCP)

Overall impact
B (75)

Commentary

Accelerated Pharma is a strong overall performer. With a 'B' rating of 74.9 for overall impact (89th percentile compared to all companies), Accelerated Pharma ranks 152nd out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 148 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 430 others. On top material causes for Accelerated Pharma's industry (Pharmaceuticals & Biotech), Accelerated Pharma performs well in Child and Maternal Health (95.0 score), Child and Maternal Health (87.7), Improved Mental Health (95.7) and 4 other causes where it received an 'A' score and performs poorly in Accountable Institutions (25.8 score).
Impact
Cause PRIVATE.ACCP
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2014
Employees
6
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Illinois, United States
Share classes
PRIVATE.ACCP
ACCP
Description
Operator of a biotech pharmaceutical company intended to develop cancer drugs. The company focuses on in-licensing late-stage drug programs for ovarian, colorectal, and small-cell lung cancer patients. It uses a drug development strategy based on individualized targeting of patients using genomics, providing the healthcare industry with novel cancer treatments.
Material causes
Ethos considers the following causes material for Accelerated Pharma, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.